Bulk Pharmaceutical API Sources for FENOFIBRATE (MICRONIZED)

Bulk Pharmaceutical API Sources for FENOFIBRATE (MICRONIZED)

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		F6020_SIGMA
Molport		MolPort-002-887-051
Hangzhou APIChem Technology		AC-4227
AKos Consulting & Solutions		AKOS005107777

Bulk Active Pharmaceutical Ingredient (API) Sources for: FENOFIBRATE (MICRONIZED)

Last updated: August 7, 2025

Introduction

Fenofibrate, particularly in micronized form, is a widely prescribed lipid-modifying agent used primarily to reduce elevated triglycerides and cholesterol levels, mitigating cardiovascular risks. As a critical component in pharmaceutical formulations, sourcing high-quality bulk API is vital for manufacturers ensuring efficacy, safety, and regulatory compliance. This report details the global landscape of fenofibrate (micronized) API suppliers, examining key manufacturing regions, quality standards, supply chain dynamics, and emerging trends.

Overview of Fenofibrate (Micronized) API

Fenofibrate belongs to the fibric acid derivative class, functioning primarily as a peroxisome proliferator-activated receptor-alpha (PPARα) agonist. Its micronized formulation enhances bioavailability, ensuring better absorption and therapeutic action. The API's manufacturing demands strict quality standards, including Good Manufacturing Practices (GMP), to meet regulatory requirements such as those set by the FDA, EMA, and other health authorities.

Global Manufacturing Landscape

Major Production Regions

India

India dominates as a primary hub for fenofibrate API production, driven by its cost advantages, robust manufacturing infrastructure, and a significant presence of API API manufacturers. Leading Indian API producers such as Orchid Pharma, Aurobindo Pharma, and Mylan (now part of Viatris) have established extensive manufacturing capacity, delivering both bulk APIs and finished pharmaceuticals globally.

China

China's API industry has historically supplied a substantial proportion of global fenofibrate API, benefiting from large-scale manufacturing facilities and favorable regulatory environments, especially prior to recent tightening. Chinese companies like Zhejiang Hisun Pharmaceutical and Zhejiang Huahai Pharmaceutical are prominent players, often serving as backward integration points within global supply chains.

European Union and United States

While less dominant in volume, European and US manufacturers are known for high-quality API production standards, often catering to markets with rigorous regulatory scrutiny. European firms such as Boehringer Ingelheim and Swiss-based Firmenich produce fenofibrate API for niche markets, leveraging strict quality controls and advanced synthesis techniques.

Emerging Manufacturing Trends

Recent trends indicate a shift toward diversification and localization of API sourcing, driven by geopolitical factors, supply chain resilience concerns, and the drive for regulatory compliance. Companies increasingly seek alternative sources to mitigate risks associated with over-reliance on Chinese and Indian providers.

Key API Suppliers for Fenofibrate (Micronized)

Indian API Manufacturers

• Aurobindo Pharma: A top-tier generic API producer offering micronized fenofibrate in compliance with international GMP standards. Their manufacturing facility adheres to US FDA, EMA, and WHO certifications, ensuring high-purity APIs suitable for global markets.
• Mylan (Viatris): Offers micronized fenofibrate API globally, with facilities compliant with multiple regulatory frameworks. Their extensive R&D capabilities enable consistent API quality.
• Torrent Pharmaceuticals: Supplies micronized fenofibrate internationally, emphasizing cost-efficiency and quality assurance.
• Cipla: Known for a broad portfolio of lipid-modifying APIs, Cipla produces micronized fenofibrate for export markets, with quality certifications aligning with global standards.

Chinese API Manufacturers

• Zhejiang Hisun Pharmaceutical: One of the largest fenofibrate API producers in China, providing micronized formulations with GMP certification and strong export capabilities.
• Zhejiang Huahai Pharmaceutical: Supplies micronized fenofibrate with comprehensive quality assurance and adherence to international standards.
• Northwest Institute of Plateau Biology (Shaanxi): Collaborates with commercial manufacturers offering quality API synthesis with focus on compliance.

European and US Suppliers

• Boehringer Ingelheim: Supplies API for proprietary formulations, often emphasizing high purity and advanced synthesis technology.
• Lonza: Provides custom manufacturing of fenofibrate APIs, leveraging single-use technology and GMP compliance.
• Sigma-Aldrich (Merck): Offers research-grade micronized fenofibrate, primarily for development purposes, with rigorous quality protocols.

Quality and Regulatory Compliance

For pharmaceutical companies, API quality standards are non-negotiable. Suppliers must provide comprehensive documentation, including Certificates of Analysis (CoA), stability data, and adherence to cGMP standards. Regulatory authorities scrutinize API batches for purity (usually >99%), residual solvents, heavy metals, and other contaminants.

Manufacturers sourcing fenofibrate (micronized) from Asia need to verify certifications, audit histories, and compliance records. International suppliers often hold certifications such as ISO 9001, GMP, and specific regional approvals to ensure regulatory acceptance across markets.

Supply Chain Considerations

• Price Dynamics: Indian and Chinese suppliers offer competitive pricing, providing a cost-effective option for large-volume needs.
• Lead Times: Geographic proximity influences delivery schedules; Indian suppliers typically offer shorter lead times than Chinese counterparts due to trade agreements.
• Regulatory Risks: Increasing scrutiny on Chinese and Indian APIs necessitates thorough qualification processes, audits, and supplier qualification programs.
• Supply Security: Diversification across regions minimizes risks related to geopolitical tensions, tariffs, and export restrictions.

Emerging Alternatives and Future Outlook

The COVID-19 pandemic and geopolitical uncertainties have accelerated the search for diversified APIs sources. Engagement with Contract Manufacturing Organizations (CMOs) and the adoption of dual-sourcing strategies are gaining traction. Additionally, some pharmaceutical firms invest in in-house manufacturing capacity to strengthen supply chain resilience, though such moves involve substantial capital expenditure and regulatory hurdles.

Advances in synthetic chemistry and process optimization may yield new high-efficiency manufacturing routes, further stabilizing supply.

Conclusion

The landscape for sourcing fenofibrate (micronized) API remains robust, characterized by leading suppliers across India, China, Europe, and the US. Indian and Chinese manufacturers provide cost-effective, high-quality APIs capable of meeting international regulatory standards, supporting the global demand for this vital lipid-modifying agent. However, regulatory compliance, supply chain resilience, and quality assurance remain critical considerations for procurers, driving ongoing diversification and rigorous supplier qualification processes.

---

Key Takeaways

• India and China dominate global fenofibrate (micronized) API production, offering cost-effective and compliant options.
• European and US suppliers focus on high-end, high-purity APIs for niche or regulated markets.
• Quality certifications (GMP, ISO) and thorough supplier audits are crucial in API sourcing.
• Supply chain diversification reduces risks and improves resilience amidst geopolitical and pandemic-related disruptions.
• Emerging trends prioritize dual-sourcing strategies and local manufacturing investments to ensure stable supply.

---

FAQs

1. What are the primary regulatory standards for sourcing fenofibrate (micronized) API?

Manufacturers must ensure APIs comply with cGMP, ISO standards, and regional approvals such as FDA, EMA, and WHO certifications. Due diligence includes analyzing Certificates of Analysis, stability data, and audit records.

2. Which regions offer the most cost-effective options for fenofibrate API?

India and China remain the most cost-effective sources due to economies of scale, manufacturing capacity, and favorable production costs.

3. How can buyers mitigate risks associated with supply disruptions from China or India?

Diversify sourcing across multiple qualified suppliers, establish dual-sourcing contracts, and consider local manufacturing options or internal capacity building.

4. Are there quality differences between APIs from different regions?

While quality standards are globally regulated, variability exists. European and US manufacturers typically adhere to more stringent standards, whereas Indian and Chinese suppliers have improved compliance through international certifications and audits.

5. What are the key factors influencing API quality beyond certification?

Consistent quality depends on robust quality control processes, validated synthesis methods, purity levels (>99%), residual solvent profiles, and comprehensive documentation and audit histories.

---

Sources:

1. [1] Global Pharmaceutical API Market Overview.
2. [2] Indian Pharmaceutical Industry Reports, Pharma IQ.
3. [3] Chinese API Manufacturing Industry Insights.
4. [4] Regulatory Guidelines for API Approval, FDA and EMA.
5. [5] Recent Trends in API Supply Chain Optimization, PharmaManufacturing.com.